ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

¿ïÃú¡¢¡¢¡¢ÁÖË®±öÍŶÓÏàÖú½ÒÏþ¸ÎÄÚµ¨¹Üϸ°û°©Ñо¿Ð§¹û

¸å¼þȪԴ£º £ºÁ¥ÊôµÚÒ»Ò½Ôº ±à¼­£º £ºÀîͯÖÛ¡¢¡¢¡¢Íõ¶¬Ã· ÉóºË£º £ºÖª×ã ÔĶÁÁ¿£º £º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Áõº£Äþ£©¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº¸Îµ¨ÒÈÍâ¿ÆÖÐÐÄ¿ïÃú½ÌÊÚÍŶÓÓ뾫׼ҽѧÑо¿ÔºÁÖË®±ö½ÌÊÚÍŶӵÄÏàÖúÑо¿Ð§¹û¡°Targeting tumor-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy¡±½ÒÏþÓÚÓ¢¹ú賦²¡Ñ§»á»á¿¯¡¢¡¢¡¢Î¸³¦ÁìÓò¶¥¼¶ÆÚ¿¯GutÔÓÖ¾£¨IF=31.79£©£¬£¬£¬¸ÃÑо¿ÆÊÎöÁ˸ÎÄÚµ¨¹Ü°©£¨ICC£©Î¢ÇéÐÎÖжàºËÐÍËèÔ´ÒÖÖÆÐÔϸ°û£¨PMN-MDSC£©ÕÙļµÄ·Ö×Óµ÷¿Ø»úÖÆ£¬£¬£¬Îª¸ÄÉÆICC¿¹PD-1ÄÍÒ©ÌṩÁËÁªºÏÖÎÁÆÐÂÕ½ÂÔ¡£


0CF8A8D8DEB96230030C82E29FF_D30969E3_9344

ͼƬ˵Ã÷£º £º¸ÎÄÚµ¨¹Ü°©METTL1Ôö½øCXCL8/Cxcl5µÄ·­ÒëÒÔÕÐļPMN-MDSC£¬£¬£¬½ø¶øÒÖÖÆCD4+Tϸ°ûµÄÀ©ÔöºÍCD4+ºÍCD8+Tϸ°ûµÄ¿¹Ö×Áö»îÐÔ£¬£¬£¬½éµ¼ICC¿¹PD-1ÄÍÒ©¡£°ÐÏòMETTL1²¢×è¶ÏCXCR2ÒÖÖÆPMN-MDSCµÄǨá㣬£¬£¬»Ö¸´CD4+ºÍCD8+Tϸ°ûµÄ¿¹Ö×Áö¹¦Ð§£¬£¬£¬¸ÄÉÆICC¿¹PD-1ÖÎÁÆÁÆÐ§¡£


78%µÄICC»¼ÕßÔÚÊ×´ÎÕï¶Ïʱ¼´ÎªÍíÆÚ£¬£¬£¬ÖÎÁÆÊÖ¶ÎÓÐÏÞ¡£ÃâÒß¼ì²éµãÒÖÖÆ¼Á¿ª·¢ÁËÍíÆÚÖ×ÁöÖÎÁƵÄÐÂģʽ£¬£¬£¬µ«ICC¶ÔÃâÒß¼ì²éµãÒÖÖÆ¼ÁµÄÓ¦´ðÂÊÏÔ×ŵÍÓÚÆäËûʵÌåÖ×Áö£¬£¬£¬ÆäDZÔÚ»úÖÆÉв»ÇåÎú¡£

ÃâÒß΢ÇéÐÎÓëÖ×ÁöµÄÏ£ÍûÒÔ¼°ÃâÒßÖÎÁƵÄÏìÓ¦Ç×½üÏà¹Ø£¬£¬£¬¿ïÃú½ÌÊÚÍŶӺÍÁÖË®±ö½ÌÊÚÍŶӻùÓÚngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº¸Î°©±ê±¾¿â£¬£¬£¬·¢Ã÷ÍíÆÚµ¨¹Ü°©ÖÐPMN-MDSC½þÈóÏÔÖøÔöÌí£¬£¬£¬ÇÒtRNA m7GÐÞÊÎøMETTL1ÓëPMN-MDSCµÄ½þÈóÇ×½üÏà¹Ø¡£»ùÒò¹¤³ÌÊóµÈ¶àÖÖÌåÄÚÄ£×ÓÕ¹ÏÖMETTL1ͨ¹ýÔö½øÖ×ÁöPMN-MDSCµÄÕÙ£¬£¬Ôö½øICCÏ£Íû¡£Í¨¹ýtRNA»¹Ô­ºÍ¼ôÇвâÐò¡¢¡¢¡¢¶à¾ÛºËÌÇÌåÏà¹ØµÄmRNA²âÐò£¬£¬£¬ÍŶӽøÒ»²½·¢Ã÷METTL1Ñ¡ÔñÐÔµ÷¿ØÇ÷»¯Òò×ÓÈËCXCL8ºÍCxcl5µÄ·­Ò룬£¬£¬×è¶ÏÇ÷»¯Òò×ÓÊÜÌå»òÇóýMETTL1¿ÉÏÔÖø¸ÄÉÆICC¿¹PD-1ÖÎÁƵÄЧ¹û¡£

¸ÃÂÛÎĵÚÒ»×÷ÕßÊÇngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº¸Îµ¨ÒÈÍâ¿ÆÖÐÐÄ¿ïÃú½ÌÊÚµÄÔÚ¶Á²©Ê¿ÉúÁõº£Äþ¡¢¡¢¡¢²©Ê¿ºóÔøÑ©ÕêºÍÔÚ¶Á²©Ê¿ÉúÈÎÐñöΡ£¿ïÃú½ÌÊÚºÍÁÖË®±ö½ÌÊÚΪÅäºÏͨѶ×÷Õß¡£¿ïÃú½ÌÊÚÓëÁÖË®±ö½ÌÊÚºã¾ÃÏàÖú̽Ìָΰ©mRNAµÄÒì³£·­Òëµ÷¿Ø×÷Ó㬣¬£¬¼ÈÍùÑо¿Ð§¹ûÕ¹ÏÖÁËmRNAÒì³£·­Òë¶Ô¸Î°©±¬·¢¿ªÕ¹µÄÒªº¦×÷Óò¢ÓÚMolecular CellµÈÔÓÖ¾½ÒÏþ¶àƪÏàÖúÂÛÎÄ¡£ÏÖ´ÓÃâÒßÐÂÊÓ½ÇÊ×´ÎÕ¹ÏÖÇ÷»¯Òò×ÓÔÚmRNA·­Òë²ãÃæ±»Òì³£µ÷¿ØµÄлúÖÆ£¬£¬£¬Îª¸ÄÉÆICC¿¹PD-1ÖÎÁÆÁÆÐ§ÌṩÁªºÏÐÂÕ½ÂÔ¡£

ÂÛÎÄÁ´½Ó£º £ºhttps://gut.bmj.com/content/early/2022/10/25/gutjnl-2022-327230


¡¾ÍøÕ¾µØÍ¼¡¿